Current oncologic applications of radiofrequency ablation therapies

Table 3 Studies involving survival using radiofrequency ablation for primary lung tumors and metastases

Ref.	Patients (tumors) n	Mean tumor size (cm)	Tumor type	Median local progression free interval	Overall survival			Complications
					1 yr	2 yr	3 yr
Ambrogi et al[1]	54 (64)	2.4	40 for NSCLC	< 3 cm - 15.8 mo	72% for NSCLC1	46% for NSCLC1	30% for NSCLC1	6 for PTX
			24 for Mets	> 3 cm - 6.6 mo	88% for Met1	72% for Mets1	NR for Mets1	1 for chest wall hematoma
Kim et al[30]	8 for RFA	3.66 for RFA	All stage I NSCLC	NR	88% for RFA	50% for RFA	25% for RFA	1 for PTX
	14 for SR	3.99 for SR			93% for SR	77% for SR	67% for SR	4 for hemoptysis
Simon et al[35]	153 (189)	2.7	75 for stage I NSCLC	< 3 cm - 45 mo	78% for NSCLC	57% for NSCLC1	36% for NSCLC1	18 for PTX
			57 for Mets	> 3 cm - 12 mo	70% for Met	54% for Mets1	44% for Mets1	5 for hemoptysis
								4 for death
Chua et al[37]	148	4	108 for CRCM	11 mo	NR	NR	60%	66 for PTX
			Other					16 for pleural effusion
			40 for Mets					1 for vleeding
Lencioni et al[61]	106 (183)	3.5	33 for NSCLC	NR	70% for NSCLC	48% for NSCLC		27 for PTX
			73 for Mets		89% for CRCM	66% for CRCM		4 for effusion
					92% for Other	64% for Other
Yan et al[62]	55	2.1	All CRCM	NR	85%	64%	46%	16 for PTX/9 requiring drainage
								5 for hemoptysis
Hiraki et al[63]	20	2.4	All stage I NSCLC	9 mo	90%	84%	74%	13 for PTX/1 requiring drainage

¹Calculated based on Kaplan-Meier survival curves. NR: Not reported; NSCLC: Non-small cell lung cancer; CRCM: Colorectal cancer metastasis; Mets: Other tumor metastases; PTX: Pneumothorax; SR: Surgical resection; RFA: Radiofrequency ablation.